This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Big Pharma CEOs Indicate More M&A Deals at JP Morgan Meeting
by Zacks Equity Research
Big pharma CEOs hint at spur in M&A activity in 2019 at the 37th J.P. Morgan Healthcare Conference.
The Zacks Analyst Blog Highlights: Amgen, Broadcom, Starbucks, Citigroup and Carnival
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, Broadcom, Starbucks, Citigroup and Carnival
Amgen's Osteoporosis Candidate Evenity Gets Approval in Japan
by Zacks Equity Research
Amgen (AMGN) gets approval in Japan for osteoporosis candidate, Evenity.
Top Stock Reports for Amgen, Broadcom & Starbucks
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), Broadcom (AVGO) and Starbucks (SBUX).
Merck Buys NASH Candidate, Keytruda Wins 5 Approvals in Japan
by Zacks Equity Research
Merck (MRK) exercises option to in-license an insulin sensitizer from NGM Biopharmaceuticals for NASH and type II diabetes. Its key drug Keytruda snaps up five new label expansion nods in Japan.
Amgen (AMGN) Stock Moves -1.52%: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $188.98 in the latest trading session, marking a -1.52% move from the prior day.
Teva (TEVA) Ends Dispute with Amgen Over Generic Sensipar
by Zacks Equity Research
Teva (TEVA) ends an ongoing patent dispute with Amgen over generic Sensipar by making an undisclosed payment.
Spectrum Pharma Fully Enrolls 1St Cohort in Poziotinib Study
by Zacks Equity Research
Spectrum Pharma (SPPI) completes enrollment in the first cohort of a phase II study on poziotinib for previously treated NSCLC patients with EGFR exon 20 insertion mutations. Shares rise.
Will Pfizer's (PFE) Stock Keep Up the Momentum in 2019?
by Zacks Equity Research
Pfizer (PFE) performs better than the industry in 2018 and looks well poised to keep the positive momentum alive in 2019.
Will AbbVie (ABBV) Shares Regain Lost Momentum in 2019?
by Zacks Equity Research
Though AbbVie's (ABBV) stock was down this year, it looks well poised for a recovery in 2019.
Spectrum Pharma Files BLA for Neutropenia Candidate Rolontis
by Zacks Equity Research
Spectrum Pharma (SPPI) petitions for a BLA to the FDA regarding its lead pipeline candidate, Rolontis, to address chemotherapy-induced neutropenia in patients with breast cancer.
Amgen (AMGN) Stock Moves -1%: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $178.40, marking a -1% move from the previous day.
AbbVie (ABBV) Seeks Approval for RA Candidate Upadacitinib
by Zacks Equity Research
AbbVie (ABBV) submits regulatory applications in the United States and EU for upadacitinib, for the treatment of adult patients with moderate to severe rheumatoid arthritis.
Merck's sBLA for Keytruda in Lung Cancer Gets Extended Review
by Zacks Equity Research
FDA extends review period for label expansion application for Merck's (MRK) Keytruda in first-line lung cancer by three months. A decision is now expected in April 2019.
Lilly's Shares Rise on Robust 2019 View, Dividend Hike
by Zacks Equity Research
Eli Lilly's (LLY) shares rise 3% on an upbeat outlook for 2019. It also hikes quarterly dividend by 15%.
Allergan Drops, Stops Textured Breast Implant Sales in Europe
by Zacks Equity Research
Allergan (AGN) halts the sale of its textured breast implants and tissue expanders in Europe. Stock declines.
Merck's Keytruda Gets FDA Approval for Rare Skin Cancer
by Zacks Equity Research
Merck (MRK) wins an accelerated approval from the FDA to expand Keytruda's label for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte
Biotech Stock Roundup: Pipeline Updates From VRTX & AMGN, ADRO Teams Up With LLY
by Zacks Equity Research
A busy week for the biotech sector with quite a few licensing deals and other regulatory updates.
Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $187.10 in the latest trading session, marking a -1.57% move from the prior day.
Merck's Keytruda Gets EU Nod as Adjuvant Therapy for Melanoma
by Zacks Equity Research
Merck (MRK) gains an EU approval for Keytruda as an adjuvant therapy pertaining to adult patients with advanced melanoma.
Teva Reports Positive Top-Line Data for Migraine Candidate
by Zacks Equity Research
Teva (TEVA) announces positive top-line data from the phase IIIb study on fremanezumab for the preventive treatment of migraine in adult patients.
Pfizer's (PFE) Biosimilar of Avastin Gets Positive CHMP Nod
by Zacks Equity Research
Pfizer (PFE) gets positive CHMP opinion for Zirabev (bevacizumab), a potential biosimilar to Roche's Avastin (bevacizumab).
5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019
by Zacks Equity Research
The big drug stocks are on a strong footing of late. Here are five such picks from the biotech and large-cap pharma space that are expected to do well in 2019 too.
5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride
by Kinjel Shah
There are some biotech stocks which are down more than 20% this year so far but have the potential to bounce back next year.